Next Article in Journal
Microvessel Density Is Associated with VEGF and α-SMA Expression in Different Regions of Human Gastrointestinal Carcinomas
Next Article in Special Issue
Surgical Treatment of Intra-Abdominal Desmoid Tumors Resulting In Short Bowel Syndrome
Previous Article in Journal
Novel Antibody-Based Proteins for Cancer Immunotherapy
Previous Article in Special Issue
Current Perspectives on Desmoid Tumors: The Mayo Clinic Approach
Cancers 2011, 3(3), 3394-3404; doi:10.3390/cancers3033394
Article

Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy

1
, 2
, 3
, 4
, 5
, 6
 and 7,*
Received: 15 August 2011; Accepted: 18 August 2011 / Published: 25 August 2011
(This article belongs to the Special Issue Desmoid Tumors)
View Full-Text   |   Download PDF [202 KB, uploaded 25 August 2011]   |   Browse Figures
Abstract: Fibromatosis, or extra-abdominal desmoid tumor, is a benign disease which often has an aggressive clinical course that can be difficult to treat. We performed a retrospective review of 16 patients (12 females and four males) with a mean age of 34.2 years treated with methotrexate and vinblastine for newly diagnosed or recurrent extra-abdominal desmoid tumor. The mean age of our patient cohort was 34.2 years (range 11–70), and the mean tumor size was 11.5 cm (range 2.5–21.2 cm). The mean duration of therapy was 12 months with an average follow-up of 43 months (range 1–149 months). Fourteen of 16 patients demonstrated a clinical response to treatment. Eight of 14 patients demonstrated a radiologic decrease in tumor size. Only one patient progressed on therapy. Six patients developed recurrent symptoms after discontinuation of treatment. Chemotherapy-related symptoms including neutropenia, nausea, and vomiting were common and observed in most patients, however these side effects were mild and transient. Five patients developed peripheral neuropathy that prompted a change from vinblastine to vinorelbine during treatment. One potentially life-threatening complication (pneumocystis pneumonia) occurred which was diagnosed early and successfully treated. The use of methotrexate and vinblastine/vinorelbine in the management of fibromatosis appears to be an effective treatment with minimal treatment-related side effects.
Keywords: fibromatosis; desmoid tumors; chemotherapy; methotrexate; vinblastine; vinorelbine fibromatosis; desmoid tumors; chemotherapy; methotrexate; vinblastine; vinorelbine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Montgomery, C.; Emory, C.; Adams, S.; Cohen, J.; Pitcher, J.D.; Potter, B.K.; Temple, H.T. Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy. Cancers 2011, 3, 3394-3404.

AMA Style

Montgomery C, Emory C, Adams S, Cohen J, Pitcher JD, Potter BK, Temple HT. Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy. Cancers. 2011; 3(3):3394-3404.

Chicago/Turabian Style

Montgomery, Corey; Emory, Cynthia; Adams, Sheila; Cohen, Jonathan; Pitcher, John David; Potter, Benjamin Kyle; Temple, H. Thomas. 2011. "Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy." Cancers 3, no. 3: 3394-3404.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert